Upgrade to SI Premium - Free Trial

Regenxbio (RGNX)

7.80 -0.10 (1.27%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/5/26)

Latest Headlines

Regenxbio Inc. (RGNX) PT Lowered to $26 at H.C. Wainwright June 8, 2026 6:54 AM - StreetInsider Form SCHEDULE 13G/A REGENXBIO Inc. Filed by: JPMORGAN CHASE & CO June 4, 2026 1:10 PM - SEC Filing Form SC TO-I REGENXBIO Inc. Filed by: REGENXBIO Inc. June 3, 2026 8:12 AM - SEC Filing Form 8-K REGENXBIO Inc. For: May 29 June 3, 2026 7:30 AM - SEC Filing Form 4 REGENXBIO Inc. For: May 29 Filed by: Tasse Daniel June 2, 2026 5:21 PM - SEC Filing Form 4 REGENXBIO Inc. For: May 29 Filed by: STUMP DAVID C June 2, 2026 5:21 PM - SEC Filing Form 4 REGENXBIO Inc. For: May 29 Filed by: Zachary Jennifer June 2, 2026 5:21 PM - SEC Filing Form 4 REGENXBIO Inc. For: May 29 Filed by: Mills Kenneth T. June 2, 2026 5:17 PM - SEC Filing Form 4 REGENXBIO Inc. For: May 29 Filed by: MIGAUSKY GEORGE V June 2, 2026 5:17 PM - SEC Filing Form 4 REGENXBIO Inc. For: May 29 Filed by: KARABELAS ARGERIS N June 2, 2026 5:16 PM - SEC Filing Form 4 REGENXBIO Inc. For: May 29 Filed by: Glucksmann Alexandra June 2, 2026 5:16 PM - SEC Filing Form 4 REGENXBIO Inc. For: May 29 Filed by: Fox Allan M. June 2, 2026 5:16 PM - SEC Filing Form 4 REGENXBIO Inc. For: May 29 Filed by: Bennett Jean June 2, 2026 5:15 PM - SEC Filing Stifel Reiterates Buy Rating on Regenxbio Inc. (RGNX) May 27, 2026 9:13 AM - StreetInsider REGENXBIO to Participate in Upcoming Investor Conferences May 18, 2026 4:05 PM - PR NewsWire Regenxbio Inc. (RGNX) PT Lowered to $16 at Morgan Stanley May 15, 2026 8:44 AM - StreetInsider Regenxbio Inc. (RGNX) PT Lowered to $10 at Goldman Sachs May 15, 2026 4:56 AM - StreetInsider Regenxbio Inc. (RGNX) PT Lowered to $12 at Barclays May 15, 2026 4:43 AM - StreetInsider Form 10-Q REGENXBIO Inc. For: Mar 31 May 14, 2026 7:31 AM - SEC Filing Form 8-K REGENXBIO Inc. For: May 14 May 14, 2026 7:15 AM - SEC Filing Regenxbio (RGNX) Misses Q1 EPS by 38c, Misses on Revenue May 14, 2026 7:12 AM - StreetInsider REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights May 14, 2026 7:10 AM - PR NewsWire REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202 May 14, 2026 7:00 AM - PR NewsWire Form 4 REGENXBIO Inc. For: May 11 Filed by: PAKOLA STEVE May 13, 2026 5:19 PM - SEC Filing Form SCHEDULE 13G REGENXBIO Inc. Filed by: STATE STREET CORP May 12, 2026 11:54 AM - SEC Filing Form 144 REGENXBIO Inc. Filed by: PAKOLA STEVE May 11, 2026 4:36 PM - SEC Filing REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting May 7, 2026 7:05 AM - PR NewsWire REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy May 6, 2026 7:05 AM - PR NewsWire Form ARS REGENXBIO Inc. For: Dec 31 April 14, 2026 5:15 PM - SEC Filing Form DEFA14A REGENXBIO Inc. April 14, 2026 5:05 PM - SEC Filing Form DEF 14A REGENXBIO Inc. For: May 29 April 14, 2026 5:00 PM - SEC Filing Form PRE 14A REGENXBIO Inc. For: May 29 April 3, 2026 4:30 PM - SEC Filing Form SCHEDULE 13G/A REGENXBIO Inc. Filed by: VANGUARD GROUP INC March 27, 2026 11:36 AM - SEC Filing Full Article List